Journal
DALTON TRANSACTIONS
Volume 43, Issue 16, Pages 6128-6131Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c3dt53582g
Keywords
-
Categories
Funding
- Beneficentia Stiftung (Vaduz, Liechtenstein)
- AIRC [IG-12085]
- Cost Action [CM1105]
Ask authors/readers for more resources
A crystallographic study of the adduct formed between hen egg white lysozyme (HEWL) and NAMI-A, an established ruthenium(III) anticancer agent in clinical trials, is presented here. The X-ray structure reveals that NAMI-A coordinates the protein, as a naked ruthenium ion, at two distinct sites (namely Asp101 or Asp119) after releasing all its original ligands (DMSO, imidazole and Cl-). Structural data of the HEWL/NAMI-A adduct are compared with those previously obtained for the HEWL adduct of AziRu, a NAMI-A analogue bearing a pyridine in place of imidazole. The present results further support the view that NAMI-A exerts its biological effects acting as a classical prodrug first undergoing activation and then causing extensive metalation of relevant protein targets. It is also proposed that the original Ru-ligands, although absent in the final adduct, play a major role in directing the ruthenium center to its ultimate anchoring site on the protein surface.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available